The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics

Schizophrenia Bulletin
S LeuchtIris E Sommer

Abstract

Most of the 13 542 trials contained in the Cochrane Schizophrenia Group's register just tested the general efficacy of pharmacological or psychosocial interventions. Studies on the subsequent treatment steps, which are essential to guide clinicians, are largely missing. This knowledge gap leaves important questions unanswered. For example, when a first antipsychotic failed, is switching to another drug effective? And when should we use clozapine? The aim of this article is to review the efficacy of switching antipsychotics in case of nonresponse. We also present the European Commission sponsored "Optimization of Treatment and Management of Schizophrenia in Europe" (OPTiMiSE) trial which aims to provide a treatment algorithm for patients with a first episode of schizophrenia. We searched Pubmed (October 29, 2014) for randomized controlled trials (RCTs) that examined switching the drug in nonresponders to another antipsychotic. We described important methodological choices of the OPTiMiSE trial. We found 10 RCTs on switching antipsychotic drugs. No trial was conclusive and none was concerned with first-episode schizophrenia. In OPTiMiSE, 500 first episode patients are treated with amisulpride for 4 weeks, followed by a 6-week dou...Continue Reading

References

Jul 1, 1990·Schizophrenia Research·D AddingtonB Schissel
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
May 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·S H JonesG Dunn
Feb 1, 1993·Acta Psychiatrica Scandinavica·A ShalevH Munitz
Jul 11, 1998·The American Journal of Psychiatry·R R ConleyS Zaremba
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanRobert M Hamer
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Aug 6, 2003·The American Journal of Psychiatry·Margaret G WoernerJohn M Kane
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 1, 2005·International Clinical Psychopharmacology·John M KaneEarl Giller
Dec 8, 2006·The American Journal of Psychiatry·Susan M EssockJeffrey A Lieberman
Jul 10, 2007·Psychopharmacology·Stefan LeuchtWerner Kissling
Jul 12, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Romain BeitingerStefan Leucht
Nov 11, 2008·Schizophrenia Research·Robert A RosenheckJeffrey Lieberman
Apr 2, 2009·Psychopharmacology·Atheir I AbbasBryan L Roth
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Feb 5, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Ragy R GirgisJeffrey A Lieberman
May 13, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·G FaberR J Van Den Bosch
Sep 8, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Oliver D HowesDavid Taylor
Jan 2, 2013·Journal of Clinical Psychopharmacology·Robin EmsleyLupe Martinez
Feb 5, 2013·The American Journal of Psychiatry·Gary RemingtonMark Sinyor

❮ Previous
Next ❯

Citations

May 12, 2018·The Cochrane Database of Systematic Reviews·Myrto T SamaraStefan Leucht
Jan 19, 2019·Translational Psychiatry·Emanuela MartinuzziUNKNOWN OPTiMiSE Study Group
Oct 21, 2019·Environmental Monitoring and Assessment·Murat GülMuratcan Gül
Dec 17, 2019·The American Journal of Psychiatry·Stefan LeuchtJohn M Davis
May 26, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Réjane TroudetStéphane Jamain
Mar 22, 2019·Health Care Analysis : HCA : Journal of Health Philosophy and Policy·Susan C C Hawthorne, Anne Williams-Wengerd
May 29, 2018·European Archives of Psychiatry and Clinical Neuroscience·G FondUNKNOWN FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
Apr 22, 2018·Molecular Psychiatry·Sameer JauharOliver D Howes
Nov 1, 2020·Nature Reviews. Cardiology·René Ernst NielsenSvend Eggert Jensen
Jan 12, 2021·Thérapie·Louise CartonRomain Guilhaumou
Mar 23, 2021·The Australian and New Zealand Journal of Psychiatry·Niranjan BidargaddiJorg Strobel
Mar 30, 2021·Frontiers in Psychiatry·Mark R Libowitz, Erika L Nurmi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here